Liminal BioSciences Inc. PFSCF

Primary Symbol: LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.

NDAQ:LMNL - Post by User

Liminal BioSciences Inc.

Bullboard Posts

Comment by MoneyCristoon May 25, 2018 1:28pm

145 Views

Post# 28081599

RE:How was Prometic Played you ask?

Bio, in all respect we only have PLI words for the delay, we never saw the exact communication or reserves from the FDA. Easy to point the finger at fda and shout corruption. Those new points of control are maybe more necessary than we could think of. Yes Plasminogen is naturally occurring in our organism, but what about all the other chemical to extract it ? One could think an injection of affinity resin straight in blood stream is no good at all...(assuming 100% is impossible) maybe it has to be controlled in such a way to prove there is no build up of undesired ligands in the organism, who knows. That said for a year delay, I think something "special" that we do not fully grasp had happened. Anyway, extended data will, I suppose, clarify a lot. But I do not see Pg approval as a slam dunk anymore.

Biofinder wrote: One word: influence.

Money (big money) owns (and controls) everything in the biotech sector, and big money buys influence and control.

Big pharma = big money = control the market = influence

Ryplazim is the human protein plasminogen, it’s not a new drug. Ryplazim is 100% safe with 100% efficacy, its been administered to patients thousands of times with no adverse events, and has around 5 years of clinical data behind it. Ryplazim is a game changer for a myriad of diseases and everybody whose anybody already knows that.

Prometic is being played by big pharma throwing their weight around behind the scenes to delay market approval of Ryplazim using the kind of influence that only their large market position can afford them. Prometic has no influence.

That’s just the way I see it, there’s no other logical explanation for the delay; all arrows point to “it’s just the way this world seems to work” -> money greases the wheels and drives the markets.

Big pharma’s “Golden Rule” = those with the gold make the rule.

IMO Ryplazim approval was suppressed (delayed) not because of any efficacy or safety reasons (as laid out in my previous post below) but because big pharma needed time.

You can believe what you what.

The Conspiracy Continues for Ryplazim

Plasminogen (Ryplazim) is produced by the liver and aids is the body’s healing process. Ryplazim IS NOT A NEW DRUG, it is a naturally occurring protein. Ryplazim is 100% pure plasminogen, medical grade and ready to go just like the liver produces it.

In the FDA approved clinical trials Ryplazim had a 100% success rate in both primary and secondary end points with 0% adverse events and 0% safety concerns.

So why the FDA one year delay for Ryplazim approval?

IMO to give the big boys (big pharma) time to digest and make plans for this ground breaking treatment; they already know that PLASMINOGEN IS THE KEY TO HUMAN HEALING IN MANY DISEASE INDICATIONS, thus when Prometic was ready to introduce Ryplazim to the world (opening the door to a whole myriad of different disease treatment) the big boys said wait a minute ... They know plasminogen is the key to healing many diseases, they know it, the medical community knows it, and any one who can read and understand the scientific data knows it.

Money talks.

There was NO VALID REASON not to give Ryplazim full marketing approval the first time around, or at the very least limited marketing approval; 100% efficacy with 0% safety concerns, come’on man...